Literature DB >> 7750986

Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.

D Reinhold1, U Bank, F Bühling, T Kähne, D Kunt, J Faust, K Neubert, S Ansorge.   

Abstract

Various studies from different laboratories have shown that the membrane ectoenzyme dipeptidyl peptidase IV (DP IV, CD26) expressed in T and NK cells is involved in the regulation of DNA synthesis and cytokine production. In this paper, we performed a biochemical and functional characterization of dipeptidyl peptidase IV on the human histiocytic lymphoma cell line U937. Using U937 clones expressing low to high levels of membrane localized CD26, we found that the synthetic reversible inhibitors of DP IV, Lys-[Z(NO2)]-thiazolidide and Lys-[Z(NO2)]-piperidide, have different effects on all functions. In U937-H cells that strongly express high levels of CD26, DP IV inhibitors were shown to suppress DNA synthesis and production of IL-1 beta, but stimulate the secretion of the IL-1 receptor antagonist (IL-1RA) and of TNF-alpha. In contrast, both inhibitors did not influence the cytokine production and DNA synthesis in U937-L cells exhibiting low level CD26 expression. These data support the hypothesis that CD26 plays a crucial role in proliferation and cytokine production, not only in T cells, but also in other cell systems, and that enzymatic activity is essential for its function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7750986     DOI: 10.1016/S0171-2985(11)80412-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  9 in total

1.  Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.

Authors:  D Reinhold; U Bank; F Bühling; U Lendeckel; J Faust; K Neubert; S Ansorge
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

2.  DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Authors:  Nga N Ta; Corinne A Schuyler; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 3.  Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.

Authors:  Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-08       Impact factor: 3.575

Review 4.  Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

Authors:  Aleksi Sedo; Jonathan S Duke-Cohan; Eva Balaziova; Liliana R Sedova
Journal:  Arthritis Res Ther       Date:  2005-10-26       Impact factor: 5.156

Review 5.  The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.

Authors:  Na-Hyung Kim; Taeyang Yu; Dae Ho Lee
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

Review 6.  Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.

Authors:  Paola Pantanetti; Giovanni Cangelosi; Giuseppe Ambrosio
Journal:  Intern Emerg Med       Date:  2020-06-26       Impact factor: 3.397

Review 7.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

8.  A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice.

Authors:  Hiroyuki Hirakawa; Hirofumi Zempo; Masahito Ogawa; Ryo Watanabe; Jun-Ichi Suzuki; Hiroshi Akazawa; Issei Komuro; Mitsuaki Isobe
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

9.  The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.

Authors:  Zrinka Bukvić Mokos; Mikela Petković; Anamaria Balić; Branka Marinović
Journal:  Croat Med J       Date:  2020-04-30       Impact factor: 1.351

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.